Colesevelam for type 2 diabetes mellitus (Protocol).
Colesevelam was originally approved for the treatment of hyperlipidaemia (high blood lipids) in the 2000s but has been shown to improve blood sugar as well. Therefore, we investigated its role in the management of type 2 diabetes mellitus. A total of 1450 patients took part in six studies investigat...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English English |
| Published: |
EBSCO Publishing
2011
|
| Online Access: | http://psasir.upm.edu.my/id/eprint/24722/ http://psasir.upm.edu.my/id/eprint/24722/1/Colesevelam%20for%20type%202%20diabetes%20mellitus.pdf |
| _version_ | 1848845114054541312 |
|---|---|
| author | Loke, Seng Cheong Ooi, Cheow Peng |
| author_facet | Loke, Seng Cheong Ooi, Cheow Peng |
| author_sort | Loke, Seng Cheong |
| building | UPM Institutional Repository |
| collection | Online Access |
| description | Colesevelam was originally approved for the treatment of hyperlipidaemia (high blood lipids) in the 2000s but has been shown to improve blood sugar as well. Therefore, we investigated its role in the management of type 2 diabetes mellitus. A total of 1450 patients took part in six studies investigating colesevelam. These studies lasted 8 to 26 weeks. Only one small study compared colesevelam directly to placebo, the other five studies investigated a combination of colesevelam with other antidiabetic agents versus a combination of placebo with other antidiabetic agents. There were no two studies with the same intervention and comparison group. When added to other antidiabetic agents colesevelam showed improvements in the control of blood glucose and blood lipids. However, it is difficult to disentangle the effects of colesevelam from the other antidiabetic agents used because only one study compared colesevelam to placebo. The same is true for adverse effects: three studies reported on just a few non-severe hypoglycaemic episodes, no other serious side effects were observed. No study investigated mortality; complications of type 2 diabetes such as eye disease, kidney disease, heart attack and stroke; health-related quality of life; functional outcomes and costs of treatment. Therefore, long-term data on the efficacy and safety of colesevelam are necessary. |
| first_indexed | 2025-11-15T08:41:40Z |
| format | Article |
| id | upm-24722 |
| institution | Universiti Putra Malaysia |
| institution_category | Local University |
| language | English English |
| last_indexed | 2025-11-15T08:41:40Z |
| publishDate | 2011 |
| publisher | EBSCO Publishing |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | upm-247222015-10-05T01:07:18Z http://psasir.upm.edu.my/id/eprint/24722/ Colesevelam for type 2 diabetes mellitus (Protocol). Loke, Seng Cheong Ooi, Cheow Peng Colesevelam was originally approved for the treatment of hyperlipidaemia (high blood lipids) in the 2000s but has been shown to improve blood sugar as well. Therefore, we investigated its role in the management of type 2 diabetes mellitus. A total of 1450 patients took part in six studies investigating colesevelam. These studies lasted 8 to 26 weeks. Only one small study compared colesevelam directly to placebo, the other five studies investigated a combination of colesevelam with other antidiabetic agents versus a combination of placebo with other antidiabetic agents. There were no two studies with the same intervention and comparison group. When added to other antidiabetic agents colesevelam showed improvements in the control of blood glucose and blood lipids. However, it is difficult to disentangle the effects of colesevelam from the other antidiabetic agents used because only one study compared colesevelam to placebo. The same is true for adverse effects: three studies reported on just a few non-severe hypoglycaemic episodes, no other serious side effects were observed. No study investigated mortality; complications of type 2 diabetes such as eye disease, kidney disease, heart attack and stroke; health-related quality of life; functional outcomes and costs of treatment. Therefore, long-term data on the efficacy and safety of colesevelam are necessary. EBSCO Publishing 2011 Article PeerReviewed application/pdf en http://psasir.upm.edu.my/id/eprint/24722/1/Colesevelam%20for%20type%202%20diabetes%20mellitus.pdf Loke, Seng Cheong and Ooi, Cheow Peng (2011) Colesevelam for type 2 diabetes mellitus (Protocol). Cochrane Database of Systematic Reviews, - (10). pp. 1-22. ISSN 1469-493X http://www.ebscohost.com/ 10.1002/14651858.CD009361 English |
| spellingShingle | Loke, Seng Cheong Ooi, Cheow Peng Colesevelam for type 2 diabetes mellitus (Protocol). |
| title | Colesevelam for type 2 diabetes mellitus (Protocol). |
| title_full | Colesevelam for type 2 diabetes mellitus (Protocol). |
| title_fullStr | Colesevelam for type 2 diabetes mellitus (Protocol). |
| title_full_unstemmed | Colesevelam for type 2 diabetes mellitus (Protocol). |
| title_short | Colesevelam for type 2 diabetes mellitus (Protocol). |
| title_sort | colesevelam for type 2 diabetes mellitus (protocol). |
| url | http://psasir.upm.edu.my/id/eprint/24722/ http://psasir.upm.edu.my/id/eprint/24722/ http://psasir.upm.edu.my/id/eprint/24722/ http://psasir.upm.edu.my/id/eprint/24722/1/Colesevelam%20for%20type%202%20diabetes%20mellitus.pdf |